Weekly Research Analysts’ Ratings Updates for Climb Bio (CLYM)

Several brokerages have updated their recommendations and price targets on shares of Climb Bio (NASDAQ: CLYM) in the last few weeks:

• 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $23.00 price target on the stock.
• 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set a “moderate buy” rating and a $23.00 price target on the stock.
• 7/27/2026 – Climb Bio had its price target raised by Wedbush from $17.00 to $20.00. They now have an “outperform” rating on the stock.
• 7/17/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – Climb Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 6/12/2026 – Climb Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $17.00 price target on the stock.
• 6/11/2026 – Climb Bio had its price target raised by BTIG Research from $19.00 to $20.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Climb Bio is now covered by Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 6/8/2026 – Climb Bio is now covered by Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 6/8/2026 – Climb Bio had its “buy” rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.